The metabolic bioactivation of a drug to a reactive metabolite (RM) and its covalent binding to cellular macromolecules is believed to be involved in clinical adverse events, including idiosyncratic drug toxicities. Therefore, it is important to assess the potential of drug candidates to generate RMs and form drugprotein covalent adducts during lead optimization processes. In this study, the RM formation of some marketed drugs were quantitatively assessed by means of a sensitive and robust detection method that we have established using 35 S-glutathione ( 35 S-GSH) as a trapping agent. Problematic drugs well-known to generate RMs exhibited a relatively high rate of 35 S-GS-adducts to RM (RM-GS) formation, which contrasted with safe drugs. For practical use in lead optimization processes, a series of new chemical entities were tested and hints on the structural modifications needed in order to minimize their RM formation were provided. Furthermore, the RM-GS formation rates of a number of compounds were compared using their in vitro covalent binding yields to liver proteins determined with 14 C-labeled compounds, demonstrating that the RM-GS formation rate could be a substitute for the covalent binding yield within the same series of compounds.
Introduction
The preclinical prediction of the adverse event (AE) profile of a new chemical entity (NCE) is an important and difficult task. Accurate prediction is extremely difficult in the case of idiosyncratic drug toxicities (IDTs), which have a very low frequency of incidence and no universal animal models for evaluation. 1) At present, there is no commonly accepted experimental approach for the prediction of IDTs. Recently, however, an increasing number of studies have suggested that the metabolic activation of a drug to a reactive metabolite (RM) and its covalent binding to cellular macromolecules is involved in the occurrence of IDTs. [2] [3] [4] Although there is no proof of a causal relationship between RM formation and the occurrence of IDTs, in the pharmaceutical industry the formation of RMs is considered to be a potential liability for drug development. Therefore, it is important to assess the potential of NCEs to generate RMs and form drug-protein covalent adducts during lead optimization processes. A covalent binding assay using a radio-labeled tracer of a NCE is the most powerful and useful method for the direct determination of the amount of RMs covalently bound to proteins. As Evans et al. reported, 5) covalent binding yields can be obtained from a variety of preclinical and human metabolism test systems, typically utilizing human liver microsomes, human hepatocytes, or rats in vivo. Although these studies can provide important and definitive parameters for risk assessment, due to the cost it is sometimes impossible to synthesize radio-labeled tracer for all NCEs during lead optimization processes. Therefore, quantitative methods for detection of RMs generated from unlabeled NCEs using trapping agents such as glutathione (GSH) is effective. These include the radiometric detection of RMs trapped with 3 H-GSH or 35 S-GSH and the fluorometric detection of RMs trapped with glutathione tagged with a dansyl group. [6] [7] [8] [9] These methods can provide quantitative information on the covalent GS-adduct to RMs (RM-GS) formation, however, it is usually difficult to assess the risks for toxic-ity of NCEs from the obtained data. Moreover, the relationship between RM-GS formation and protein-adduct to RM (RM-protein) formation remains unclear.
In this study, we aimed to quantitatively assess the RM-GS formation of marketed drugs including`problematic drugs' well-known to generate RMs such as ticlopidine, clozapine, and diclofenac, and`safe drugs' not associated with bioactivation such as levofloxacin and caffeine. For practical application, we tried to assess a series of NCEs during lead optimization process based on the obtained reference data. Furthermore, this study was also intended to investigate the relationship between the RM-GS formation rate obtained from a GSH trapping assay and the RM-protein formation rate obtained from a covalent binding assay.
The method for RM trapping using dansyl-GSH in human microsomal system reported by Gan et al. 7) utilizes fluorometric detection for quantification. In this method, the fluorescence of test compounds or their metabolites may interfere with fluorometric detection and quantification of dansyl-GS-adduct to RMs. In addition, the intensity of LC-fluorometric detection is highly affected by solvents used. Therefore, radiometric detection of RMs is considered to provide more quantitative and precise data than fluorometric detection. Hartman et al. 8) developed the method for quantitative detection of RMs trapped with intracellularly generated 35 S-GSH in human hepatocytes. In this method, the RM-GS formation would be greatly affected by several factors, such as, incorporation of test compounds into hepatocytes and lot-to-lot variation in activity of drug metabolizing enzymes and GSH biosynthetic enzymes. While the method using hepatocytes preincubated with 35 S-methionine is applicable for some qualitative assessment, it seems inappropriate for the quantitative screening in the light of throughput, robustness and reproducibility. Pooled human liver microsomal system provides data with lower variance than the hepatocyte- 35 S-methionine system. For these reasons, we employed the method using 35 S-GSH in human liver microsomal system to collect comparable data from a variety of marketed drugs and NCEs. A replication study of the previously reported method 9) revealed that it was difficult to assign and integrate the radioactive RM-GS peaks on the radio-chromatograms accurately and reproducibly since the yield of the RM-GS generated from in vitro incubation was very low relative to unchanged excess 35 S-GSH. Thus, we first had to optimize the incubation and analytical conditions of the reported method in order to improve its sensitivity and accuracy and then establish a robust method that can provide reliable and reproducible data.
Methods
Materials: Acetaminophen, diclofenac, clozapine, furosemide, indomethacin, nefazodone, flutamide, sulfamethoxazole, zomepirac and carbamazepine were purchased from Sigma Chemical Co. (St. Louis, MO). Caffeine was purchased from Fluka (Buchs, Switzerland). 35 S-GSH and unlabeled GSH were obtained from PerkinElmer (Wellesley, MA) and Sigma Chemical Co., respectively. Levofloxacin, procainamide, moxifloxacin, ticlopidine, tienilic acid and compounds A-E were synthesized in Daiichi Pharmaceutical Co., Ltd. Pooled human liver microsomes (HLM, n＝50, gender mixed, 20 mg of protein/mL) were obtained from XenoTech (Kansas City, KS). All other chemicals and reagents were of analytical grade and were available from commercial sources.
14 C-labeled compounds of NCEs were obtained from Daiichi Pure Chemicals Co., Ltd (Ibaraki, Japan).
Incubation conditions: Each test compound was dissolved in acetonitrile: methanol (9:1, v/v) to prepare 10 mM stock solution. The incubation mixture of each test compound with 35 S-GSH and HLM contained the following: 100 mM test compound, 0.2 mM and 925 kBq/tube 35 S-GSH, 2 mg of protein/mL HLM, 25 mM glucose 6-phosphate (G6P), 2 units/mL glucose 6-phosphate dehydrogenase (G6PDH), 10 mM MgCl2, and 100 mM potassium phosphate buffer (pH 7.4). This mixture was preincubated for 3 min at 379 C. A reaction was initiated by the addition of b-NADP ＋ to reach a final concentration of 2.5 mM. The final incubation volume was 0.5 mL. Samples not containing test compound but containing vehicle solution (acetonitrile: methanol＝9:1) were used as a negative control. After 30 min of incubation, the reaction was terminated by the addition of 0.5 mL of ice-cold acetonitrile. After vortexing and centrifugation, the resulting supernatant was removed to another tube, followed by concentrating for 2.5 h using a centrifuge evaporator system (CC-105 and TU-055, TOMY, Tokyo, Japan; GVD-050A, Shinku-Kiko, Tokyo, Japan). Then, 50 mL of the concentrated solution was analyzed by radio-HPLC.
Detection of 35 S-RM-GS: For the sample analysis, an HPLC system consisting of L-7100 pump (HITACHI, Tokyo, Japan), L-7250 autosampler (HITACHI), L-5090 degasser (HITACHI), 655A-52 column oven (HITACHI) and D-7000 interface (HITACHI) was used. The HPLC system was equipped with a 4.6 mm I.D.×150 mm L., 5 mm column (TSK gel ODS-100V, TOSOH, Japan), a 3.2 mm I.D.×15 mm L., 5 mm guard column (TSK guardgel ODS-100V, TOSOH) and a radio activity detector (RAD) (b-RAM model 3, IN/US System, USA). Samples were separated using a linear gradient mobile phase system at a flow rate of 1 mL/min. The initial chromatographic conditions were 10 mM ammonium acetate:acetonitrile (95:5, v/v), followed by a linear increase of acetonitrile to 25% from 10 to 15 min, followed by a linear gradient to 50% from 15 to 20 min, followed by a linear gradient to 90% from 20 to 24 min. The ratio was kept at 90% aceonitrile until 27 min and was then returned to the ini-tial running condition. Liquid scintillator (LumaFlow A, Lumac, Holland) was also eluted at a flow rate of 2 mL/min. Software for LC-RAD analysis (Laura 3.1, Lablogic Systems, England) was used for the quantification of the adducts. A correction constant, f [counts/dpm] for the experiment was calculated from the total radioactivity counts observed on the radio-chromatogram of a 20-fold-diluted sample and its radioactivity was measured using a liquid scintillation counter (LSC-6100, Aloka, Japan).
In vitro covalent binding of radioactivity to human liver microsomes: The binding studies methods were based on those previously reported. 9) Briefly, the 14 C-labeled compounds (10 mM, 0.2 Ci per tube) were incubated at 379 C with human liver microsomes (1 mg/tube) in 100 mM potassium phosphate buffer (pH 7.4) containing 10 mM MgCl2, 2 units/mL G6PDH, 25 mM G6P, and with or without 2.5 mM b-NADP ＋ in a total volume of 0.5 mL. Reactions were initiated by the addition of b-NADP ＋ , and after a 60 min incubation, they were terminated with 0.5 mL of acetonitrile. After centrifugation, the precipitated protein was washed twice with 80% (v/v) aqueous methanol containing 10% (w/v) trichloroacetic acid, twice with methanol-diethyl ether (1:1, v/v), and twice with 80% aqueous methanol. The resulting precipitate was dissolved in 0.5 mL of 1 N NaOH at 559 C for 12 h. Following neutralization with 1 N HCl, a BCA protein assay kit was used to determine the protein concentrations in the solutions. A liquid scintillation counter with Hionic-fluor scintillation fluid cocktail was used to determine the final amount of radioactivity in the solutions. The following equations were used to calculate covalent binding yield. 
Results
Drugs which are well-known to be associated with clinical AEs, including IDTs due to metabolic bioactivation, namely`problematic drugs' such as ticlopidine, clozapine, and diclofenac were tested by means of the previously reported method.
9)
The observed radiochromatograms are shown in Figure 1 . The radioactive peaks with integration on the radio-chromatograms for the complete incubations were considered as RM-GS peaks, however, they were not very clear, and thus could not be assigned and integrated accurately and objectively. Then we modified the method in terms of the following incubation and analytical conditions: the substrate concentration, the GSH concentration, the negative control incubation, the gradient program for HPLC analysis, the concentration condition before HPLC injection, and the calculation of RM-GS formation rate. The substrate concentration was changed from 10 to 100 mM, resulting in an augmentation of the RM-GS peaks, for instance, an approximately 3-fold increase for clozapine. The total GSH concentration was increased from 0.1 to 0.2 mM by the addition of unlabeled GSH based on the preliminary examination. This modification resulted in a reduction of the noise level on the radio-chromatograms without affecting the signal level. The pattern of the noise peaks on the radio-chromatogram obtained from the complete incubation could be represented by that of (-)substrate incubation, but not by that of (-)NADP incubation (preliminary observation), therefore (-)substrate incubation was adopted as a negative control in place of (-)NADP incubation. Regarding the gradient program for HPLC, the final proportion of the organic solvent was increased in order to completely elute any highly lipophilic compounds. The concentration condition before HPLC injection and the calculation of the RM-GS formation rate were modified in order to enhance the signals on the radio-chromatogram. The radio-chromatograms obtained with the all-modified method are also shown in Figure  1 . In the cases of ticlopidine and clozapine, the modified method provided more distinct RM-GS peaks on the radio-chromatograms than the former method. The signal-to-noise (S/N) ratio on the radio-chromatogram was improved approximately 10-fold after the modification of the incubation and analytical conditions. In the case of diclofenac, no obvious RM-GS adduct peak could be observed on the radio-chromatogram of the complete incubation compared to that of the negative control, whereas the modified method gave a small but distinct peak that was not observed on the control chromatogram. The intra-and inter-day accuracy were checked using ticlopidine, clozapine and diclofenac as substrates, as shown in Table 1 . The CV values of the intra-and inter-day variations of the method were within 18% and 15%, respectively. Fig. 1 . Radio-chromatograms of samples obtained from the reported 9) (A) and modified (B) incubation and analytical systems using ticlopidine, clozapine and diclofenac as substrates. The peaks with integration on the radio-chromatograms for the complete incubations were considered as RM-GS peaks. Next, other problematic drugs such as acetaminophen, carbamazepine, flutamide, furosemide, indomethacin, nefazodone, procainamide, sulfamethoxazole, tienilic acid, and zomepirac were tested using the modified method.`Safe drugs' which are not associated with bioactivation, such as levofloxacin, moxifloxacin and caffeine, were also tested for the purpose of comparison. The RM-GS formation rates of the drugs tested are summarized in Figure 2 . For the problematic drugs tested, the RM-GS peaks were observed and their formation rates calculated. The calculated RM-GS formation rates for ticlopidine, nefazodone, clozapine, and acetaminophen were relatively high, showing 47, 37, 20, and 18 [pmol/min/mg protein], respectively. Exceptionally, no RM-GS peak was detected on the radio-chromatograms for carbamazepine, indomethacin, and zomepirac, which are also known to form RMs. The safe drugs such as levofloxacin, moxifloxacin and caffeine exhibited no RM-GS peak on their radio-chromatograms.
In order to put this method to practical use during the lead optimization process, a series of NCEs for development, compounds A-E, were also tested in this assay and the results are shown in Table 2 . Compound A with a benzothiophene moiety showed RM formation, and the RM-GS formation rate was calculated to be 17 [pmol/min/mg protein]. Compounds B and C, which are the derivatives of compound A, and also have a benzothiophene moiety, exhibited RM formation as well, and their RM-GS formation rates were 16 and 21 [pmol/min/mg protein], respectively. On the other hand, no RM-GS formation was observed for compounds D and E, which are benzofuran and methyl-indole analogues of compound A, respectively.
In order to investigate the relationship between RM-GS and RM-protein formation, we compared the RM-GS formation rates obtained in this assay with the covalent binding yields determined by the incubation of radio-labeled compounds with human liver microsomes for NCEs and marketed drugs. The covalent binding yields of the marketed drugs were cited in the previous report 9) and those of the NCEs were collected based on the reported method.
9)
The plots of the covalent binding yields versus the RM-GS formation rates of the compounds tested are shown in Figure 3 . The covalent binding yields of the compounds that exhibited more than 10 [pmol/min/mg protein] of RM-GS formation rates were all more than 50 [pmol/mg protein], whereas those of the compounds with no GS-adduction were all less than 50 [pmol/mg protein]. The correlation coefficient r between the covalent binding yields and the RM-GS adduct formation rates was calculated to be 0.80. Furthermore, the compounds tested are classified in Figure 3 according to their structures as follows: the thiophene-containing compounds (Thiophene), the aromatic amine-containing compounds that are known to form quinone imines (Quinone imine), a series of NCEs with aryl halide moiety (Aryl halide), furan-containing compound (Furan), and the other compounds without well-known problematic sub-structures (Others). Within each group, the RM-GS formation seemed to highly correlate with the covalent binding.
Discussion
The present assay method provided highly sensitive detection of radioactive RM-GS peaks on the radiochromatograms due to the modifications in the incubation and analytical conditions, as shown in Figure 1 . The improvement of the S/N ratio on the radiochromatograms is considered to be mainly due to augmentation of the signals by the increase of the substrate concentration and the reduction of noise by the increase of the total GSH concentration. The signal enhancement was also thought to be assisted by the modifications in the concentration conditions of the samples for HPLC analysis and the calculation of the RM-GS formation rate. In the previous method, the RM-GS formation rate was calculated from the peak-to-total area ratio on the radiochromatograms. Therefore, the HPLC sample could not be fully concentrated, in order for the strongest peak of the unreacted 35 S-GSH not to exceed the upper limit of radioactivity detection, resulting in a loss of sensitivity. In the present method, the supernatant after incubation was concentrated to less than 100 mL and a large fraction (50 mL) of the sample was injected onto the HPLC system, giving the maximum signal on the radio-chromatograms. In this case, because the peak of the unreacted 35 S-GSH was saturated, the total radioactivity of the samples injected onto the HPLC system was determined using a liquid scintillation counter and the RM-GS formation rate was calculated. In addition, the use of (-)substrate incubation as a control allowed us to judge and integrate the RM-GS peaks objectively and precisely.
As shown in Table 1 , the intra-and inter-day variations of RM-GS formation rates for ticlopidine, clozapine and diclofenac were within 20% as CV values, indicating the repeatability and robustness of this assay. Because the RM-GS peak derived from diclofenac was the smallest detectable one with an S/N ratio of approximately 2.0, the quantification limit of this assay was considered to be approximately 1.0 [pmol/min/mg protein].
Numerous drugs are known to undergo metabolic bioactivation and generate RMs. 10, 11) Ticlopidine and tienilic acid with a thiophene moiety undergo CYPmediated oxidation to form reactive thiophene-S-oxide and epoxide, respectively. 12, 13) Diclofenac, acetaminophen, flutamide and nefazodone are bioactivated to reactive quinine-imine species via CYP oxidation. [14] [15] [16] [17] The major RMs generated from clozapine and furosemide by CYP-mediated metabolism are considered to be a nitrenium ion and furan epoxide, respectively. 18, 19) Procainamide and sulfamethoxazole are known to form reactive nitroso metabolites. 20, 21) These drugs exhibited RM-GS formation, which contrasted with the safe drugs, as shown in Figure 2 , demonstrating that this assay can assess CYP-mediated RM formation. The RM formation of cabamazepine and indomethacin is reported to be mainly mediated by myeloperoxidase in activated neutrophils, 22, 23) and zomepirac is known to be bioactivated to acyl glucuronide by UDP-glucuronosyltransferase. 24) Therefore no observed RM-GS formation from the liver microsomal incubation with carbamazepine, indomethacin or zomepirac would be reasonable.
Since this assay can provide quantitative information regarding RM formation without a radio-labeled tracer, it seemed to be usefully applicable to lead optimization. According to the application experiment, the RM-GS formation rates of in-house compounds A, B and C with a benzothiophene moiety as a side chain were considered to be comparable to those of the problematic drugs acetaminophen, and clozapine, suggesting the high risk of AEs including IDTs due to bioactivation. RM-GS formation was not detected with compounds D and E or the safe drugs, indicating the low risk of AEs due to liver microsomal bioactivation. The lack of RM-GS formation of compound D with benzofuran and compound E with methyl indole in place of benzothiophene demonstrates that reactive intermediates should be derived from the benzothiophene moiety and thus it will be crucial to avoid benzothiophene in the structural optimization of this series of compounds. Benzothiophenes are reported to be metabolized to the electrophilic reactive species benzothiophene S-oxides and arene oxides. 25) Accordingly, this assay would be useful for optimizing the structure of a series of compounds to RM formation. Meanwhile, both benzofuran and indole substructures are also well known to form RMs via CYP-mediated oxidation. Benzofuran-containing compounds such as bergamottin undergo bioactivation to form a reactive epoxide intermediate. 26) Indole-containing compounds such as 3-methylindole and indomethacin are known to form reactive epoxide and quinone imine species. 23, 27) Because enzymatic production of RMs depends on the whole-structure and physicochemical property of the substrate, any compounds containing these substructures do not universally produce RMs.
According to the comparative study shown in Figure  3 , the RM-GS formation rate was not as highly correlated with the RM-protein yield using radio-labeled compounds. This observation seems to be mainly due to the difference between GSH and liver microsomal proteins in their reactivity to RMs. Although GSH can react with a broad range of electrophilic RMs, GSH cannot trap some types of RMs, for example, iminium ions, acyl glucuronides, radical species and aldehydes which generally do not form stable adducts with GSH, 28) probably due to lower reactivity and the reversibility of the reaction. In addition, the life time and partition (protein/aqueous) of the RMs are considered to affect the selectivity between GSH and protein in adduct formation. The structural classification of the compounds tested seems to improve the correlation between GSH and protein adduction, indicating that RM-GS formation could be an alternative marker for the covalent binding yields within the same series of compounds. The previous report 9) showed the clear correlation between RM-GS and RM-protein formation, which is conflicting with our results that RM-GS yield does not necessarily correlate with covalent binding to proteins. This inconsistency would arise from the differences in the variations of drugs tested and conditions of RM trapping by 35 S-GSH in these works. We believe that our observation that the RM-GS formation rate was not as highly correlated with the RM-protein yield would be reasonable and realistic, because it is based on the data of a wider variety of drugs obtained by the refined method than those in the previous work.
In conclusion, we determined the RM-GS formation rates of a number of marketed problematic and safe drugs by means of a sensitive and robust detection method using 35 S-GSH that we have established. Problematic drugs well-known to generate RMs, such as ticlopidine, nefazodone, clozapine, and acetaminophen, exhibited relatively high rate of RM-GS formation, which contrasted with safe drugs such as levofloxacin and caffeine, suggesting that RM-GS formation could be a marker of AEs including IDTs due to liver microsomal bioactivation. For a case study, RM-GS formation of a series of NCEs was assessed based on the obtained reference data and hints on the structural modifications needed in order to minimize their RM formation were provided. The relationship between the GSH adduction and covalent binding to liver protein was also investigated and the RM-GS formation rate could be an alternative marker of the covalent binding yields within the same series of compounds. The quantitative assessment of RM-GS formation is thought to be useful for minimizing the risk of metabolism-based toxicities, including IDTs, in advance of a covalent binding assessment during lead optimization processes.
